DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsour...
Dare Bioscience, Inc. (DARE)
Last dare bioscience, inc. earnings: 8/14 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.darebioscience.com/investor-relations
Company Research
Source: GlobeNewswire
Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in 10–15 minutes, and improve arousal sensations based on clinically-validated endpoints. Market introduction of DARE to PLAY™ is expected to mark a breakthrough in women’s sexual health and represents important progress toward closing one of medicine’s most persistent gender gaps. SAN DIEGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Dare´ Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that providers in select states can now begin prescribing DARE to PLAY™ Sildenafil Cream, a proprietary topical arousal cream designed specifically for women to enhance genital blood flow and arousal response. DARE to PLAY™ represents the first and only evid
Show less
Read more
Impact Snapshot
Event Time:
DARE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DARE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DARE alerts
High impacting Dare Bioscience, Inc. news events
Weekly update
A roundup of the hottest topics
DARE
News
- Dare Bioscience (NASDAQ:DARE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-MaximizationGlobeNewswire
- Daré Bioscience Receives $3.6 Million in Additional Grant FundingGlobeNewswire
- Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript [Seeking Alpha]Seeking Alpha
- Earnings To Watch: Dare Bioscience Inc (DARE) Reports Q3 2025 Result [Yahoo! Finance]Yahoo! Finance
DARE
Earnings
- 11/13/25 - Beat
DARE
Analyst Actions
- 12/2/25 - HC Wainwright
DARE
Sec Filings
- 12/1/25 - Form 8-K
- 11/25/25 - Form 1-A
- 10/6/25 - Form SCHEDULE
- DARE's page on the SEC website